This collaboration is managed by the NIHR Office for Clinical Research Infrastructure.
+44 (0)20 3794 7380
The NIHR Dementia Translational Research Collaboration (D-TRC) provides a network of world-leading investigators who are available to work with industry to further research and develop new treatments for dementia.
Our researchers are experts in translating new discoveries in dementia research from basic science into the clinic, and can provide access to patients from multiple sites across England.
The Dementia TRC is open to developing partnerships with companies to carry out experimental medicine investigations in:
These investigations focus on biomarker discovery and validation, early diagnosis, patient stratification, phase I and phase II experimental medicine and proof of concept trials.
For more information please visit the NIHR Dementia Translational Research Collaboration website.
The Dementia TRC undertakes commercial and non-commercial studies with industry partners. It is open to collaborations with any life sciences company, including pharmaceutical and diagnostic companies.
It will consider fully-funded projects as well as projects that will look for third party funding.
A feasibility study for intensive phenotyping of early Alzheimer's disease patients is being funded by the NIHR and the Medical Research Council. It aims to identify a multi-modal marker or prodromal disease for use in stratification or selection for clinical trials or use in monitoring change.
The study is in pilot phase; testing the feasibility in a multi-centre trial and acceptability to participants of very complex repeated measures including imaging, electrophysiology and molecular measures, as well as many other potential biomarkers. This pilot will lay the foundation for a larger follow on study.
Parkinson's UK has provided the Dementia TRC with funding to search for elusive Parkinson's Disease biomarkers in blood and cerebrospinal fluid using proteomics (both mass spectrometry based technologies and arrays). Identifying reliable biomarkers would transform the diagnosis and management of Parkinson's and would also speed up research to develop the next generation of treatments to slow or stop the progression of the condition.
Researchers from the Dementia TRC, in collaboration with leading UK and US biotechnology companies, are using blood samples and information collected through the largest ever in-depth study of people with Parkinson's.